Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Editorial, Opinion Piece Respond To Closure Of Murdered Abortion Provider Tiller's Clinic
Two newspapers recently published an editorial and an opinion piece in reaction to the announcement that murdered Kansas abortion provider George Tiller"s Wichita clinic would be permanently closed. The clinic was one of a handful in the U.S. offering abortion procedures in the second and third trimesters. Summaries appear below.~ Kansas City Star: The closing of Tiller"s clinic is "a tragedy for American democracy," and the "irrational violence" of his death has "trumped public policy," a Star editorial states. "The basis of civilization is that we agree to submit to the rule of law in order for society to flourish," the editorial says, adding that Tiller"s murder is "antithetical to that principle. It is dismaying to see a killer achieve his objective." The editorial notes that Tiller provided abortion services in "tragic cases" involving women "at risk of infertility or death; fetuses with severe abnormalities; and victims of rape and incest." It continues that the "reduction or loss of that service will create hardships and may put women"s lives at risk." Hospitals and doctors who refer such cases to abortion providers "must reassess the circumstances under which they would perform late-term abortions," according to the editorial. In addition, the "medical profession must take a role in training and supporting doctors willing to provide abortions," and the government and local police "must do all they can to protect a legal medical practice," the editorial says. It concludes, "Democracy demands that we not allow murder to make de facto public policy" (Kansas City Star, 6/11).~ Eric Zorn, Chicago Tribune: The announcement that Tiller"s clinic will remain permanently closed "was simply more proof that violence and intimidation can get results where civil discourse and political process fail," Tribune columnist Zorn writes. "The question isn"t whether prominent foes of abortion rights are being honest with us when they decry Tiller"s violent death and express regret over the means used to achieve an end they"ve sought," Zorn writes, adding, "Some are, I"m sure." He continues that abortion-rights opponents "recognize that ... a movement calling itself "pro-life"can"t also be pro-murder" and "are politically savvy enough to know that the gains won by terrorist acts are grudging and difficult to sustain." He continues that to "make terrorism less effective, and thereby discourage it," abortion-rights advocates, the medical profession, politicians and law enforcement officials "need to reopen that clinic in Wichita and assure its safe operation ... to defy terrorism, if for no other reason." He concludes that "as long as abortion remains legal, this same coalition needs to strive to expand the number of facilities where it"s available" (Zorn, Chicago Tribune, 6/11).
generic viagra online
National Organization for Women Establishes Kansas Abortion-Rights PAC To Fill Void After Death Of Abortion Provider Tiller
The Kansas chapter of the National Organization for Women has formed its own political action committee to replace ProKanDo, a PAC founded in 2002 by abortion provider George Tiller that was closed after his murder in May, the AP/Hays Daily News reports. ProKanDo spent more than $1 million over the last four years to advocate for abortion rights, assist candidates who support abortion rights and oppose antiabortion-rights candidates. The organization had more than 6,400 contributors but received between one-third and one-half of its annual funding from Tiller, according to former Director Julie Burkhart.NOW has scheduled a conference in Wichita on July 25 to discuss legislative strategy and Kansas elections. Marla Patrick, coordinator of NOW"s Kansas chapter,÷ said that although the new PAC will not have the same financial support from Tiller that ProKanDo received, his death has invigorated grassroots support. She added, "I think that can be every bit as effective, if not more so, especially in light of all the recent events" (Hegeman, AP/Hays Daily News, 7/18).
News of the day
AGTC And National Neurovision Research Institute Collaborate, Funding Research In Two Genetic Retinal Diseases
Applied Genetic Technologies Corporation (AGTC), a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that AGTC has entered into an agreement with the National Neurovision Research Institute (NNRI), the clinical trial support organization for the Foundation Fighting Blindness(FFB), to collaborate in experiments using the AAV delivery system in the treatment of two genetic retinal diseases known to cause blindness at an early age. The research will be coordinated by AGTC and will be conducted at The University of Florida, Oregon Health & Science University, The University of Pennsylvania, and The University of British Columbia.
Diagnostics

CHMP Recommends Expanded Use Of ISENTRESS(R) (raltegravir), From MSD, In Adult Patients With HIV-1 Infection

Merck, Sharp & Dohme (MSD) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending expanded marketing authorisation for ISENTRESS® (raltegravir) in combination with other antiretroviral (ARV) medicinal products for the treatment of HIV-1 infection in all appropriate adult patients, including patients starting HIV therapy for the first time (treatment-naç¯ve), as well as treatment-experienced patients. The positive opinion will be reviewed by the European Commission, which grants marketing authorisation to the 27 countries that are members of the European Union (EU), as well as Iceland and Norway. Raltegravir, the first and only approved integrase inhibitor, is currently approved in more than 80 countries across six continents for use in combination with other ARV agents for the treatment of HIV-1 infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing ARV therapy. The U.S. Food and Drug Administration recently approved an expanded indication for raltegravir in combination with other antiretroviral medicines for the treatment of HIV-1 infection in adult patients that includes patients starting HIV therapy for the first time, as well as treatment-experienced patients. In markets outside the United States, the use of raltegravir in treatment-naive patients is investigational and not currently licensed in this patient group. About Raltegravir Raltegravir works by inhibiting the insertion of HIV-1 DNA into human DNA by the integrase enzyme and has demonstrated rapid antiviral activity. Inhibiting integrase from performing this essential function limits the ability of the virus to replicate and infect new cells. There are drugs in use that inhibit two other enzymes critical to the HIV-1 replication process "protease and reverse transcriptase" but raltegravir is the only drug approved that inhibits the integrase enzyme. Raltegravir is a single 400 mg tablet taken twice daily without regard to food. Raltegravir does not require boosting with ritonavir. Merck & Co., Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009